257 related articles for article (PubMed ID: 26558747)
21. Exosomes in Systemic Sclerosis: Messengers Between Immune, Vascular and Fibrotic Components?
Colletti M; Galardi A; De Santis M; Guidelli GM; Di Giannatale A; Di Luigi L; Antinozzi C
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31487964
[No Abstract] [Full Text] [Related]
22. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
Hasegawa M; Fujimoto M; Takehara K; Sato S
J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
[TBL] [Abstract][Full Text] [Related]
23. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.
Jerjen R; Nikpour M; Krieg T; Denton CP; Saracino AM
J Am Acad Dermatol; 2022 Nov; 87(5):937-954. PubMed ID: 35131402
[TBL] [Abstract][Full Text] [Related]
24. Emerging drugs and therapeutics for systemic sclerosis.
Lee JJ; Pope JE
Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
[TBL] [Abstract][Full Text] [Related]
25. Strategy for treatment of fibrosis in systemic sclerosis: Present and future.
Yanaba K
J Dermatol; 2016 Jan; 43(1):46-55. PubMed ID: 26782006
[TBL] [Abstract][Full Text] [Related]
26. Systemic sclerosis sine scleroderma: distinct features in a large Brazilian cohort.
Marangoni RG; Rocha LF; Del Rio AP; Yoshinari NH; Marques-Neto JF; Sampaio-Barros PD
Rheumatology (Oxford); 2013 Aug; 52(8):1520-4. PubMed ID: 23661427
[TBL] [Abstract][Full Text] [Related]
27. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
28. N-TproBNP as biomarker in systemic sclerosis.
Schioppo T; Artusi C; Ciavarella T; Ingegnoli F; Murgo A; Zeni S; Chighizola C; Meroni PL
Clin Rev Allergy Immunol; 2012 Dec; 43(3):292-301. PubMed ID: 22669751
[TBL] [Abstract][Full Text] [Related]
29. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies.
Harris ML; Rosen A
Curr Opin Rheumatol; 2003 Nov; 15(6):778-84. PubMed ID: 14569210
[TBL] [Abstract][Full Text] [Related]
30. Current Trends in Vascular Biomarkers for Systemic Sclerosis: A Narrative Review.
Fioretto BS; Rosa I; Matucci-Cerinic M; Romano E; Manetti M
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835506
[TBL] [Abstract][Full Text] [Related]
31. Vascular complications of scleroderma.
Guiducci S; Giacomelli R; Cerinic MM
Autoimmun Rev; 2007 Sep; 6(8):520-3. PubMed ID: 17854742
[TBL] [Abstract][Full Text] [Related]
32. Systemic sclerosis: An update in 2016.
Desbois AC; Cacoub P
Autoimmun Rev; 2016 May; 15(5):417-26. PubMed ID: 26802722
[TBL] [Abstract][Full Text] [Related]
33. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality.
Nussinovitch U; Shoenfeld Y
Autoimmun Rev; 2011 Mar; 10(5):259-66. PubMed ID: 20863903
[TBL] [Abstract][Full Text] [Related]
34. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development.
Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D
Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814
[TBL] [Abstract][Full Text] [Related]
35. Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis.
Koch AE; Distler O
Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S3. PubMed ID: 17767741
[TBL] [Abstract][Full Text] [Related]
36. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.
Nordenbaek C; Johansen JS; Halberg P; Wiik A; Garbarsch C; Ullman S; Price PA; Jacobsen S
Scand J Rheumatol; 2005; 34(4):293-7. PubMed ID: 16195162
[TBL] [Abstract][Full Text] [Related]
37. Systemic sclerosis: an update.
Varga J
Bull NYU Hosp Jt Dis; 2008; 66(3):198-202. PubMed ID: 18937632
[TBL] [Abstract][Full Text] [Related]
38. Targeting vascular disease in systemic sclerosis.
Kowal-Bielecka O
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):401-7. PubMed ID: 17214586
[TBL] [Abstract][Full Text] [Related]
39. Role of microRNA in the pathogenesis of systemic sclerosis tissue fibrosis and vasculopathy.
Henry TW; Mendoza FA; Jimenez SA
Autoimmun Rev; 2019 Nov; 18(11):102396. PubMed ID: 31520794
[TBL] [Abstract][Full Text] [Related]
40. The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis.
Thachil J
Med Hypotheses; 2009 Mar; 72(3):291-3. PubMed ID: 19036527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
